Treatment of nocturnal disturbances and excessive daytime sleepiness in Parkinson's disease

Neurology

Volumn 63, Issue 8 SUPPL. 3, 2004, Pages

  Barone, Paolo ^a   Amboni, Marianna ^a   Vitale, Carmine ^a   Bonavita, Vincenzo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMITRIPTYLINE; ANTIHISTAMINIC AGENT; ANTIPARKINSON AGENT; APOMORPHINE; ATYPICAL ANTIPSYCHOTIC AGENT; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLONAZEPAM; CLONIDINE; CLOZAPINE; CODEINE; DESMOPRESSIN; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; OLANZAPINE; OPIATE; PERGOLIDE; PRAMIPEXOLE; PSYCHOSTIMULANT AGENT; QUETIAPINE; RIVASTIGMINE; ROPINIROLE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

AKINESIA; ANTICHOLINERGIC EFFECT; BRAIN DEPTH STIMULATION; DEMENTIA; DEPRESSION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DYSTONIA; EXCESSIVE DAYTIME SLEEPINESS; HALLUCINATION; HUMAN; INSOMNIA; MENTAL DISEASE; NEUROLOGIC DISEASE; NIGHT SLEEP; NOCTURIA; PANIC; PARASOMNIA; PARKINSON DISEASE; POLYSOMNOGRAPHY; POLYURIA; PRIORITY JOURNAL; PSYCHOSIS; RESTLESS LEGS SYNDROME; REVIEW; SIDE EFFECT; SLEEP DISORDER; SLEEP WAKING CYCLE; SUBTHALAMIC NUCLEUS; SYMPTOMATOLOGY; TREMOR; URINE INCONTINENCE;

EID: 7044251840     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.63.8_suppl_3.s35     Document Type: Review

References (48)

1. Askenasy JJ. Sleep in Parkinson's Disease. Acta Neurol Scand 1993;87:167-170.
2. Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study. Mov Disord 1999;14:922-927.
3. Kumar S, Bhatia M, Behari M. Sleep disorders in Parkinson's disease. Mov Disord 2002;17:775-781.
4. Fabbrini G, Barbanti P, Aurilia C, et al. Excessive daytime sleepiness in de novo and treated Parkinson's disease. Mov Disord 2002;17:1026-1030.
5. Dinges DF. The influence of the human circadian timekeeping system on sleep. In: Kriger MH, Roth T, Dement WC, eds. Principles and practice of sleep medicine. Philadelphia: WB Saunders, 1989:153-162.
6. Barone P. Clinical strategies to prevent and delay motor complications. Neurology 2003;61(suppl 3):S12-16.
7. Olanow W, Schapira AH, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci 2000; 23(suppl 10):S117-126.
8. Van Der Kechove, Jacquy J, Garce M, De Deyn PP. Sustained-release levodopa in parkinsonian patients with nocturnal disabilities. Acta Neurol Belg 1993;93:32-39.
9. Jansen EN, Meerwaldt JD. Madopar HBS in nocturnal symptoms of Parkinson's disease. Adv Neurol 1990;53:527-531.
10. Pahwa R, Busenbark K, Huber SJ, et al. Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease. Neurology 1993;43:677-681.
11. Pastor P, Tolosa E. Cabergoline in the treatment of Parkinson's disease. Neurologia 2003;18:202-209.
12. Baas HK, Schueler P. Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease. Eur Neurol 2001;46(suppl 1):S18-23.
13. Chaudhuri KR, Bhattacharya K, Porter MC, et al. The use of cabergo-line in nocturnal pakinsonian disabilities causing sleep disruption: a parallel study with controlled-release levodopa. Eur J Neurol 1999; 6(suppl 5):S11-15.
14. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998;55(suppl 1):23-30.
15. Hogl B, Rothdach A, Wetter TC, Trenkwalder C. The effect of cabergo-line on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease. Neuropsychopharmacology 2003;28:1866-1870.
16. Reuter I, Ellis CM, Chaudhuri K. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand 1999;100:163-167.
17. Cianchetti C. Dopamine agonists and sleep in man: In: Wauquier A, Gaillard JM, Monti JM, Radulovacki M, eds. Sleep: neurotransmitters and neuromodulators. New York: Raven Press, 1985:121.
18. Arnulf I, Bejjani BP, Garma L, et al. Improvement of sleep architecture in PD with subthalamic nucleus stimulation. Neurology 2000;55:1732-1734.
19. Uchiyama T, Sakakibara R, Hattori T, Yamanishi T. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon. Mov Disord 2003;18:573-578.
20. Jankovich J. Levodopa strengths and weaknesses. Neurology 2002; 58(suppl 1):S19-32.
21. Seki S, Igawa Y, Kaidoch K, et al. Role of dopamine D1 and D2 receptors in the micturition reflex in conscious rats. Neurourol Urodyn 2001; 20:105-113.
22. Yoshimura N, Mizuta E, Yoshida O, Kuno S. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys. J Pharmacol Exp Ther 1998;286:228-233.
23. Clemett D, Jarvis B. Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging 2001;18:277-304.
24. Suchowersky O, Furtado S, Rohs G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson's disease. Mov Disord 1995;10:337-340.
25. Movement Disorders Task Force. Management of Parkinson's disease: an evidence based review. Mov Disord 2002;17(suppl 4):S1-165.
26. D'Souza C, Gupta A, Alldrick MD, Sastry BS. Management of psychosis in Parkinson's disease. Int J Clin Pract 2003;57:295-300.
27. Happe S, Schrodl B, Faltl M, et al. Sleep disorders and depression in patients with Parkinson's disease. Acta Neurol Scand 2001;104:275-280.
28. Silvestri R, Pace-Schott EF, Gersh T, et al. Effects of fluvoxamine and paroxetine on sleep structure in normal subjects: a home-based night-cap evaluation during drug administration and withdrawal. J Clin Psychiatry 2001;62:642-652.
29. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003;2:229-237.
30. Saint-Cyr JA, Taylor AE, Lang AE. Neuropsychological and psychiatric side effects in the treatment of Parkinson's Disease. Neurology 1993; 43(suppl. 6):S47-52.
31. Koller WC. Disturbance of recent memory function in parkinsonian patients on anticholinergic therapy. Cortex 1984;20:307-311.
32. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings for an open trial. Mov Disord 2001;16:1171-1174.
33. Brunner H, Wetter TC, Hoegl B, et al. Microstructure of the non-rapid eye movement sleep electroencephalogram in patients with newly diagnosed Parkinson's disease: effects of dopaminergic treatment. Mov Disord 2002;17:928-933.
34. Ondo WG, Dat Vuong K, Khan H, et al. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 2001;57:1392-1396.
35. Askenasy JJ. Sleep disturbances in Parkinsonism. J Neural Transm 2003;110:125-150.
36. Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson's disease and restless legs syndrome. Arch Neurol 2002;59:421-424.
37. Ohayon MM, Roth T. Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res 2002;53:547-554.
38. Garcia-Borreguero D, Odin P, Serrano C. Restless syndrome and PD: a review of the evidence for a possible association. Neurology 2003; 61(suppl 3):S49-55.
39. O'Keeffe ST, Noel J, Lavan JN. Restless legs syndrome in the elderly. Postgrad Med J 1993;69:701-703.
40. Linazasoro G, Marti Masso JF, Suarez JA. Nocturnal akathisia in Parkinson's disease: treatment with clozapine. Mov Disord 1993;8:171-174.
41. Arnulf I, Konofal E, Merino-Andreu M, et al. Parkinson's disease and sleepiness-an integral part of PD. Neurology 2002;58:1019-1024.
42. Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999;52:1908-1910.
43. Ferreira JJ, Galitzky M, Montastruc JL, Rascol O. Sleep attacks and Parkinson's disease treatment. Lancet 2000;355:1333-1334.
44. Schapira A. Sleep attacks (sleep episodes) with pergolide. Lancet 2000; 355:1332-1333
45. Paus S, Brecht HM, Koster J, et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson' disease. Mov Disord 2003;18:659-667.
46. Zesiewicz TA, Hauser RA. Sleep attacks and dopamine agonists for Parkinson's disease. What is currently known? CNS Drugs 2003;17:593-600.
47. Hogl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002;25:905-909.
48. Adler CH, Caviness JN, Hentz JG, et al. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003;18:287-293.